Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=41347412&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Near-infrared carbon dots enable ultra-sensitive fluorometric detection of belzutifan: a novel approach for real-time therapeutic drug monitoring in cancer treatment #MMPMID41347412
Goda MN; Alqarni LS; Al-Namshah KS; Ibrahim H; El-Wekil MM; Ali R; Ali ABH
Anal Methods 2025[Dec]; ? (?): ? PMID41347412show ga
Belzutifan, a hypoxia-inducible factor-2alpha (HIF-2alpha) inhibitor, represents a breakthrough therapeutic agent for treating von Hippel-Lindau disease-associated tumors and advanced renal cell carcinoma, necessitating precise therapeutic drug monitoring. This work presents the first application of near-infrared carbon dots (NIR-CDs) for belzutifan detection utilizing a dual-mechanism approach combining aggregation-induced quenching and inner filter effect for enhanced analytical performance. The NIR-CDs were synthesized from sulfosalicylic acid and ethylenediamine precursors, exhibiting strong near-infrared emission at 750 nm upon 290 nm excitation with excellent photostability and pH tolerance. The developed fluorometric sensor demonstrated outstanding analytical performance with a linear detection range of 5.0-130.0 ng mL(-1) and a limit of detection of 1.35 ng mL(-1), which is approximately 10(3) to 10(4) times lower than therapeutic plasma concentrations. Plasma sample analysis showed excellent extraction recovery ranging from 96.6% to 98.1% across three concentration levels with relative standard deviations below 4.27%. The method demonstrated successful clinical validation through analysis of plasma samples from rats, achieving excellent correlation with reference LC-MS/MS methods while providing real-time therapeutic drug monitoring capabilities. This represents the first fluorometric approach for belzutifan quantification and establishes a new paradigm for anticancer drug monitoring that combines the advantages of carbon dot nanotechnology with clinically relevant near-infrared detection, offering significant potential for point-of-care therapeutic drug monitoring in oncology practice.